PDF herunterladen
Planta Med 2025; 91(04): 167-172
DOI: 10.1055/a-2523-3856
Reviews

Real-World Data to Document the Use of Herbal Medicinal Products in Children – Report of a Workshop in Krakow

Nico Symma
1   Pharma Deutschland e. V., Bonn, Germany
,
Andreas Hensel 
2   Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Germany
5   Foundation Plant for Health, Neumarkt, Germany
,
Bernd Roether
3   Bionorica SE, Neumarkt, Germany
5   Foundation Plant for Health, Neumarkt, Germany
,
Barbara Steinhoff 
1   Pharma Deutschland e. V., Bonn, Germany
5   Foundation Plant for Health, Neumarkt, Germany
,
Rudolf Bauer 
4   Institute of Pharmaceutical Sciences – Pharmacognosy, University of Graz, Austria
5   Foundation Plant for Health, Neumarkt, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

The workshop “Real-world data to document the use of phytopharmaceuticals in children” was organized by the GA Foundation Plants for Health in collaboration with multiple international scientific societies on July 14, 2024, during the International Congress on Natural Products Research in Kraków, Poland. The event focused on leveraging real-world data and real-world evidence to support the use of herbal medicinal products (syn. phytopharmaceuticals) in pediatric care. The workshop aimed to discuss the current state and future approaches for utilizing real-world data/real-world evidence in expanding the use of herbal medicinal products in children and adolescents. Therefore, the workshop highlighted the unmet needs and challenges in documenting the effectiveness and safety of herbal medicinal products in children and emphasized the coordinated exchange and collaboration among academia, industry, and regulatory authorities. After an e-symposium in May 2022 with more than 300 participants and an in-person workshop on this topic in Bonn in June 2023, this workshop in Krakow was the third event of its kind hosted by the Foundation Plants for Health. Participants concluded that interdisciplinary collaboration is highly needed to establish qualified methods of data collection and assessment of real-world data, e.g., establishing requirements to incorporate nonprescription herbal medicinal products into electronic patient records and registries that can be accessed by all stakeholders.

Keywords

children - phytotherapy - herbal medicinal products - real-world data - dosages


Publikationsverlauf

Eingereicht: 21. November 2024

Angenommen nach Revision: 20. Januar 2025

Artikel online veröffentlicht:
11. Februar 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Hensel A, Bauer R, Heinrich M, Hempel G, Kelber O, Kraft K, Lehmann B, Medà MM, Neiber K, Roether B, Rollinger JM, Wiebelitz R. Rationalising optimal dosing of phytotherapeutics for use in children: Current status – potential solutions – actions needed. Planta Med 2024; 90: 416-425
    Thieme ConnectPubMedSuche in Google Scholar
  • 2 Hensel A, Bauer R, Heinrich M, Kraft K. Consensus statement on the outcome of a workshop on paediatric phytotherapy: Rationalizing optimal dosing for use in children by real-world data. Planta Med 2023; 89: 1442-1443
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Vojinovic D, Hunt N. DARWIN EU® – Drug utilisation study on medicinal use of Pelargonii radix; D2.2.3 – Study Protocol for P3-C1-002; version V3.1; Darwin EU Coordination Centre. Accessed on 2025-01-27 at: https://catalogues.ema.europa.eu/system/files/2024-05/DARWIN%2520EU_D2.2.3_Protocol_P3-C1-002_DUS_Pelargonium%2520radix_v3.1_Public_0.pdf
    PubMed
  • 4 Hölzle SS, Reineke T, Hoch S, Roether B, Francis M, Anquez-Traxler C, Symma N. Basic requirements and framework conditions of Real-World Data (RWD) on herbal medicinal products. Planta Med 2024; 90: 1056-1058
    Thieme ConnectPubMedSuche in Google Scholar
  • 5 Martin D, Konrad M, Adarkwah CC, Kostev K. Reduced antibiotic use after initial treatment of acute respiratory infections with phytopharmaceuticals: a retrospective cohort study. Postgrad Med 2020; 132: 412-418
    CrossrefPubMedSuche in Google Scholar
  • 6 Lasky T, Carleton B, Horton DB, Kelly LE, Bennett D, Czaja AS, Czaja AS, Gifkins D, Osokogu OU, McMahon AW. Real-world evidence to assess medication safety or effectiveness in children: Systematic review. Drugs Real World Outcomes 2020; 7: 97-107
    CrossrefPubMedSuche in Google Scholar
  • 7 Nieber K, Raskopf E, Möller J, Kelber O, Fürst R, Shah-Hosseini K, Singh J, Kraft K, Mösgens R. Pharmaco-epidemiological research on herbal medicinal products in the paediatric population: Data from the PhytoVIS study. Eur J Pediatr 2020; 179: 507-512
    CrossrefPubMedSuche in Google Scholar
  • 8 Arlett P, Kjaer J, Broich K, Cooke E. Real-world evidence in EU medicines regulation: Enabling use and establishing value. Clin Pharmacol Ther 2022; 111: 21-23
    CrossrefPubMedSuche in Google Scholar
  • 9 Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo-Marañon M, Rueckbeil M, Cohet C, Kurz X. Marketing authorization applications made to the European medicines agency in 2018–2019: What was the contribution of real-world evidence?. Clin Pharmacol Ther 2022; 111: 90-97
    CrossrefPubMedSuche in Google Scholar